Nine years in-market experience for patients with SLE

Now Approved for Lupus Nephritis

BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. The subcutaneous (SC) formulation is approved for patients aged ≥18. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.

Icon: New Patient

How to start a new patient on BENLYSTA

Learn More

GET TO KNOW BENLYSTA

SEE THE RESULTS OF BLISS-LN

Icon: Lung

Renal response

Icon: Person

Renal-related events

Watch how BENLYSTA works

BENLYSTA is the first and only approved lupus treatment designed to target BLyS, an underlying cause of lupus1-3

BENLYSTA SELECTIVELY INHIBITS SOLUBLE BLyS, AN IMPORTANT FACTOR IN SLE1-3

Nephrology
  1. In many patients with SLE, higher concentrations of BLyS promote increased B-cell survival, including the survival of autoreactive B cells.1
  2. BENLYSTA is a targeted human monoclonal antibody that binds to soluble BLyS, inhibiting its binding to B-cell receptors.2 BENLYSTA does not bind to B cells directly, but by binding to BlyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
  3. By reducing the autoreactive B-cell population, BENLYSTA decreases the production of autoantibodies.

MEET A PATIENT WITH LUPUS NEPHRITIS WHO COULD BENEFIT FROM BENLYSTA

Icon: Study Information

Learn about the data in patients with SLE

View the Trial Data

Your lupus nephritis patients can now benefit from BENLYSTA